Seattle-based NanoString (NASDAQ:NSTG) is a leading provider of life science tools for translational research and molecular diagnostic products. The partnership will combine CareDx's clinical expertise and extensive transplant registries with NanoString's technological capabilities and development expertise to provide the transplant community with solutions that bring precision medicine to histopathology. Under the terms of the agreement CareDx will utilize NanoString's nCounter^® technology in conjunction with the newly introduced Human Organ Transplant panel, a 770-gene panel designed to evaluate the human immune response following organ transplantation.

"This partnership will further enhance the development of molecular assays in transplantation and help to improve transplant diagnostics," said Michael Mengel, Professor Department of Laboratory Medicine & Pathology, University of Alberta, Canada. "The Banff classification has already integrated recommendations for use of molecular diagnostics in diagnosing transplant rejection, and tools like HistoMap can enhance and help standardize the diagnostic process with the goal to advance patient management, guide therapy, and improve outcomes."

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

This press release includes forward-looking statements, including statements regarding CareDx's strategic partnership with Nanostring and its expected benefits and results. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including the risk that partnership does not create the benefits and opportunities anticipated by CareDx and risks related to technology development, among other risks discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.